Drug Profile
AskBio 009
Alternative Names: Adeno-associated virus serotype 8 Factor IX gene therapy; AskBio-009; BAX 335; FIX gene therapyLatest Information Update: 17 Jan 2023
Price :
$50
*
At a glance
- Originator Asklepios BioPharmaceutical
- Developer Asklepios BioPharmaceutical; Baxter International
- Class Gene therapies
- Mechanism of Action Factor IX stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Haemophilia B
Most Recent Events
- 10 Dec 2022 Updated adverse events data from a phase I/II trial in Haemophilia B presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
- 08 Aug 2019 AskBio 009 is still in phase I/II trial for Hemophilia B in USA (IV) (NCT01687608)
- 22 Sep 2015 Phase-I/II development for Haemophilia B is ongoing in USA (NCT01687608)